CapsoVision reports 10% year-over-year revenue growth and targets regulatory submissions for two key products by late 2026.
CapsoVision expects FDA clearance for its AI Highlights software by the end of Q3 2026, with plans to submit its CapsoCam Colon device for approval in Q4. The company cited steady execution of its commercial strategy during the quarter.
Revenue rose 10% year-over-year in Q2 2026, reflecting progress in its product pipeline. Management highlighted advancements in its portfolio, including the upcoming regulatory milestones for AI-driven diagnostic tools.
The company did not disclose immediate market reactions to the announcements, focusing instead on operational and regulatory updates.